These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 16996842

  • 1. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A.
    Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
    [Abstract] [Full Text] [Related]

  • 2. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A.
    Circulation; 2003 Jun 17; 107(23):2926-31. PubMed ID: 12771010
    [Abstract] [Full Text] [Related]

  • 3. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
    Parker AB, Yusuf S, Naylor CD.
    Am Heart J; 2002 Dec 17; 144(6):941-7. PubMed ID: 12486418
    [Abstract] [Full Text] [Related]

  • 4. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
    Alsheikh-Ali AA, Wang PJ, Rand W, Konstam MA, Homoud MK, Link MS, Estes NA, Salem DN, Al-Ahmad AM.
    Am Heart J; 2004 Jun 17; 147(6):1061-5. PubMed ID: 15199356
    [Abstract] [Full Text] [Related]

  • 5. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
    Raml A, Schmekal B, Grafinger P, Biesenbach G.
    Dtsch Med Wochenschr; 2001 Nov 23; 126(47):1327-30. PubMed ID: 11719857
    [Abstract] [Full Text] [Related]

  • 6. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 23; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 7. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 8. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 08; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 9. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R.
    Pharmacoepidemiol Drug Saf; 2007 Jan 08; 16(1):55-64. PubMed ID: 16470693
    [Abstract] [Full Text] [Related]

  • 10. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
    Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL.
    Am Heart J; 2004 Nov 08; 148(5):883-8. PubMed ID: 15523322
    [Abstract] [Full Text] [Related]

  • 11. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM.
    Circulation; 2005 Jul 05; 112(1):39-47. PubMed ID: 15983243
    [Abstract] [Full Text] [Related]

  • 12. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM.
    Circulation; 2006 Dec 05; 114(23):2474-81. PubMed ID: 17101852
    [Abstract] [Full Text] [Related]

  • 13. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF Investigators.
    Am J Cardiol; 2012 Mar 01; 109(5):693-8. PubMed ID: 22152974
    [Abstract] [Full Text] [Related]

  • 14. Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates.
    Raebel MA, Ross C, Cheetham C, Petersen H, Saylor G, Smith DH, Wright LA, Roblin DW, Xu S.
    Pharmacoepidemiol Drug Saf; 2010 Jan 01; 19(1):19-25. PubMed ID: 19937982
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
    Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA.
    J Am Coll Cardiol; 2005 Feb 01; 45(3):391-9. PubMed ID: 15680718
    [Abstract] [Full Text] [Related]

  • 16. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB, Rao K, Sawyer R, Gottlieb SS.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):845-9. PubMed ID: 16139135
    [Abstract] [Full Text] [Related]

  • 17. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP, Aaronson KD, Koelling TM.
    Am Heart J; 2004 Dec 06; 148(6):971-8. PubMed ID: 15632880
    [Abstract] [Full Text] [Related]

  • 18. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M, Pogue J, Kindermann I, Pöss J, Koon T, Yusuf S.
    Eur J Heart Fail; 2014 Mar 06; 16(3):325-33. PubMed ID: 24464788
    [Abstract] [Full Text] [Related]

  • 19. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
    Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1959-66. PubMed ID: 17996561
    [Abstract] [Full Text] [Related]

  • 20. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 13; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.